Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PRKCA | P17252 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17812749 | 0.98 | NAAA (0.48) | NAAAHCAR2EPHX1TSHRPSEN1 | |
| SCHEMBL16086397 | 0.98 | NAAA (0.48) | NAAAHCAR2EPHX1TSHRPSEN1 | |
| SCHEMBL17812789 | 0.98 | NAAA (0.48) | NAAAHCAR2EPHX1TSHRPSEN1 | |
| SCHEMBL3104104 | 0.94 | ALDH1A1 (0.47) | NAAAHCAR2EPHX1TSHRPSEN1 | |
| SCHEMBL16086254 | 0.93 | NAAA (0.43) | NAAAHCAR2EPHX1TSHRPSEN1 | |
| SCHEMBL16086076 | 0.93 | NAAA (0.43) | NAAAHCAR2EPHX1TSHRPSEN1 | |
| SCHEMBL16086400 | 0.91 | NAAA (0.46) | NAAAHCAR2EPHX1TSHRPSEN1 | |
| SCHEMBL17812502 | 0.91 | NAAA (0.46) | NAAAHCAR2EPHX1TSHRPSEN1 | |
| SCHEMBL16086712 | 0.91 | NAAA (0.46) | NAAAHCAR2EPHX1TSHRPSEN1 | |
| SCHEMBL16086087 | 0.91 | NAAA (0.42) | NAAAHCAR2EPHX1TSHRPSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2781522-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUND, ASYMMETRIC CATALYST, AND METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANE COMPOUND USING SAID CATALYST | Sumitomo Chemical Company, Limited (JP) | 2014-09-24 | — | — | EP | disclosed |
| US-8222240-B2 | Use of substituted cyclopropane acid derivatives for producing drugs for use in the treatment of metabolic syndrome | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-07-17 | — | — | US | disclosed |
| EP-1827415-B1 | CYCLOPROPANE ACID DERIVATIVES FOR THE REDUCTION OF LIPID LEVELS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-01-20 | — | — | EP | disclosed |
| US-20090088474-A1 | USE OF SUBSTITUTED CYCLOPROPANE ACID DERIVATIVES FOR PRODUCING DRUGS FOR USE IN THE TREATMENT OF METABOLIC SYNDROME | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-04-02 | — | — | US | disclosed |
| US-20080045590-A1 | USE OF SUBSTITUTED CYCLOPROPANE ACID DERIVATIVES FOR PRODUCING DRUGS FOR USE IN THE TREATMENT OF METABOLIC SYNDROME | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045590-A1 | USE OF SUBSTITUTED CYCLOPROPANE ACID DERIVATIVES FOR PRODUCING DRUGS FOR USE IN THE TREATMENT OF METABOLIC SYNDROME | CYP27A1, CYP11B2, CYP11B1 | NAAA 2435/4885HCAR2 272/4885EPHX1 1093/4885 |
| US-20090088474-A1 | USE OF SUBSTITUTED CYCLOPROPANE ACID DERIVATIVES FOR PRODUCING DRUGS FOR USE IN THE TREATMENT OF METABOLIC SYNDROME | FFAR1, FFAR2, FFAR3 | NAAA 1075/4885HCAR2 70/4885EPHX1 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.